Immuron Ltd has released a press release.
IMC investment in leading gut health biotech Ateria Health
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- Immuron Update on IMM-124E SARS-CoV-2 Research
- North American Travelan Sales up 494%, Global sales up 431%
- European Patent Notification on Drug Composition for CDI
- US DoD NMRC files IND application with FDA
- US DoD Uniformed Services University Clinical Update
Later from Immuron
- Immuron completes strategic investment in Ateria Health
- Immuron Receives FDA Approval for Travelan IND Application
- Business Update Presentation
- Immuron Q3 Sales reach 150% of 1H Sales
- Q3 FY23 Business Update Presentation
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron